Komori
J

J Frontier Co.,Ltd.

2934FoodMicro cap
1,937JPY-4.3%
★ Watch (sign-up required)
Price history
¥1,937Latest-22.5%
Drag across the chart to measure the move between two points.Delayed 15 minutes · monthly closing basis
Business overview

This report discloses the business operations and strategy of a corporate group whose core businesses comprise digital promotion, direct-to-consumer sales and a healthcare platform, primarily in the healthcare sector. These businesses include the online sale of pharmaceuticals and health foods, the planning and development of proprietary-brand products, and the operation of the one-stop medical platform "SOKUYAKU," which includes collaboration with medical institutions. The company is listed on the Growth Market of the Tokyo Stock Exchange (currently the Growth Market) and prepares consolidated financial statements covering 11 subsidiaries, as well as 1 non-consolidated subsidiary that is not subject to the equity method. Its operations are divided into 3 reporting segments: the Medical Care Sales Business, the Healthcare Sales Business and the Healthcare Marketing Business. These comprise businesses related to the "SOKUYAKU" medical platform service, the direct-to-consumer sale of health foods and cosmetics centered on the same brand, and brand promotion, BPO support and wholesale operations. The group aims to continue growing by expanding SOKUYAKU and creating a healthcare ecosystem that includes pre-symptomatic care and disease prevention.

Recurring subjects
No threads yetThis company's filings have not been read yet. We are adding them progressively.
Companies sharing a theme
Loading
Key numbersShowing 8 of 18
PER
128.13How many years of earnings it would take to buy the stock. The market average is generally considered to be around 15.
PBR
6.89How many times the company's net assets? Around 1x is generally considered a benchmark.
ROE
-20.9%Earning power. A figure above 10% is generally considered good.
Dividend yield
0.0%The annual dividend as a percentage of the share price.
Market capitalization
¥11bnShare price × number of shares. The value of the entire company.
Equity ratio
12.8%The proportion of assets funded by money that does not have to be repaid.
Operating margin
1.4%The percentage of revenue remaining from the company’s core business.
Revenue growth (3 years)
9.7%The average annual growth in sales over the past three years.
What to watch next
Results of implementing the SOKUYAKU pricing revision, including its impact on average revenue per user, usage frequency, gross margin and profitability
From disclosures in July 2026 onward, with the impact to be confirmed in the next earnings release and quarterly resultsImpact HighLikelihood Medium
Expansion in the adoption of SOKUYAKU Benefit, including its contribution to corporate customer acquisition and retention through employee-benefits programs
From summer 2026 onward, with the number of customers and membership trends to be confirmed through timely disclosures and earnings releasesImpact MediumLikelihood Medium
Updates to SOKUYAKU's healthcare ecosystem KPIs, QAU and ARR, and verification of their growth rates
The next disclosure cycle, quarterly or annualImpact MediumLikelihood High
What to watch next
Loading
Who owns itTop holders total 131.4%
Listed holders 131.4%Everyone else 0.0%
Nakamura Atsuhiro (中村 篤弘)96.00%
株式会社篤志18.74%
HUMEDIT SINGAPORE PTE.LTD.4.75%
株式会社プレミアム・キャピタル・マネジメント3.00%
SIX SIS LTD.2.87%
松原 明男1.62%
MSIP CLIENT SECURITIES1.38%
蓮見 智威1.11%
2 other listed holders1.92%
Who owns it
HolderOwnership (%)
Nakamura Atsuhiro (中村 篤弘)96.00
株式会社篤志18.74
HUMEDIT SINGAPORE PTE.LTD.4.75
株式会社プレミアム・キャピタル・マネジメント3.00
SIX SIS LTD.2.87
松原 明男1.62
MSIP CLIENT SECURITIES1.38
蓮見 智威1.11
2 other listed holders1.92
This company's documents
Timely disclosures
Threads